MedTrace Logo

A Phase II Study of Tegafur/Uracil (UFUR®)Plus Thalidomide for the Treatment of Advanced or Metastatic Hepatocellular Carcinoma (HCC)

NCT00384800 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2009-02-09

No results posted yet for this study

Summary

Primary objective:

To evaluate the overall response rate of tegafur/uracil (UFUR®) and thalidomide in the treatment of advanced or metastatic hepatocellular carcinoma.

Secondary objectives:

1. To determine the disease stabilization rate;
2. To assess the progression-free survival and overall survival;
3. To establish the safety profile;
4. To evaluate the changes of circulating factors indicating the angiogenesis activity and their correlation with objective tumor response.

Conditions

  • Carcinoma, Hepatocellular

Interventions

DRUG

Thalidomide(THADO), Tegafur/Uracil(UFUR)

Sponsors & Collaborators

  • Far Eastern Memorial Hospital

    lead OTHER

Principal Investigators

  • Kun Huei Yeh, Ph.D. · Far Eastern Memorial Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00384800 on ClinicalTrials.gov